Q&A Panel Discussion: Overcoming Toxicity & Immunogenicity Challenges

Time: 9:25 am
day: Day Two

Details:

• Does it depend on the disorder?
• What are best preclinical models for toxicology risk assessment?
• Reviewing preclinical data for CNS and systemic toxicity
• How does this translate into humans?
• Discussing immunogenicity concerns for patients

Speakers: